1-(3-phenoxyphenyl)-3-phenylprop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 1-(3-phenoxyphenyl)-3-phenylprop-2-en-1-one
• 化学式: C₂₁H₁₆O₂
• 分子量: 300.357
• InChiKey: AIDRVNSGSRTXPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-phenoxyphenyl)-3-phenylprop-2-en-1-one 在 氢氧化三丁基甲甲基铵 、 双氧水 、 potassium carbonate 作用下， 以 水 、 二甲基亚砜 、 丙酮 为溶剂， 反应 16.0h， 生成 4-oxo-4-(3-phenoxyphenyl)-2-phenylbutanamide
  参考文献：
  名称：

  Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents

  摘要：

  A series of triclosan mimic diphenyl ether derivatives have been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv. The binding mode of the compounds at the active site of enoyl-acyl carrier protein reductase of M. tuberculosis has been explored. Among them, compound 10b was found to possess antitubercular activity (minimum inhibitory concentration = 12.5 mu g/mL) comparable to triclosan. All the synthesized compounds exhibited low levels of cytotoxicity against Vero and HepG2 cell lines, and three compounds 10a, 10b, and 10c had a selectivity index more than 10. Compound 10b was also evaluated for log P, pKa, human liver microsomal stability, and % protein binding, in order to probe its druglikeness. Based on the antitubercular activity and druglikeness profile, it may be concluded that compound 10b could be a lead for future development of antitubercular drugs.

  DOI：

  10.2147/dddt.s104037
• 作为产物：
  描述：

  3-羟基苯乙酮 在 吡啶 、 copper diacetate 、 potassium hydroxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 72.0h， 生成 1-(3-phenoxyphenyl)-3-phenylprop-2-en-1-one
  参考文献：
  名称：

  Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents

  摘要：

  A series of triclosan mimic diphenyl ether derivatives have been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv. The binding mode of the compounds at the active site of enoyl-acyl carrier protein reductase of M. tuberculosis has been explored. Among them, compound 10b was found to possess antitubercular activity (minimum inhibitory concentration = 12.5 mu g/mL) comparable to triclosan. All the synthesized compounds exhibited low levels of cytotoxicity against Vero and HepG2 cell lines, and three compounds 10a, 10b, and 10c had a selectivity index more than 10. Compound 10b was also evaluated for log P, pKa, human liver microsomal stability, and % protein binding, in order to probe its druglikeness. Based on the antitubercular activity and druglikeness profile, it may be concluded that compound 10b could be a lead for future development of antitubercular drugs.

  DOI：

  10.2147/dddt.s104037

文献信息

• Pyrazoles and Pyrazolines as Anti-Inflammatory Agents
  作者：Martha Mantzanidou、Eleni Pontiki、Dimitra Hadjipavlou-Litina

  DOI：10.3390/molecules26113439

  日期：——

  The five-membered heterocyclic group of pyrazoles/pyrazolines plays important role in drug discovery. Pyrazoles and pyrazolines present a wide range of biological activities. The synthesis of the pyrazolines and pyrazole derivatives was accomplished via the condensation of the appropriate substituted aldehydes and acetophenones, suitable chalcones and hydrazine hydrate in absolute ethanol in the presence

  吡唑/吡唑啉的五元杂环基团在药物发现中起着重要作用。吡唑和吡唑啉具有广泛的生物活性。吡唑啉和吡唑衍生物的合成是通过合适的取代醛和苯乙酮、合适的查耳酮和水合肼在无水乙醇中在冰醋酸滴存在下缩合来完成的。化合物以良好的收率 68-99% 获得，其结构经 IR、1 H-NMR、13 C-NMR 和元素分析证实。在体外研究了新的衍生物因为它们的抗氧化、抗脂质过氧化 (AAPH) 活性和脂氧合酶的抑制活性。这两类都强烈抑制脂质过氧化。化合物2g是最有效的脂氧合酶抑制剂 (IC 50 = 80 µM)。还确定了对角叉菜胶诱导的爪水肿 (CPE) 和伤害感受的抑制，其中化合物2d和2e是最有效的。化合物2e对伤害感受的抑制高于2d。吡唑啉2d被发现在初步试验中具有活性，用于研究抗佐剂诱发的疾病 (AID) 活性。发现吡唑啉衍生物比吡唑更有效。对最有效的 LOX 抑制剂2g 的对接研究突出了与 VAL126、PHE143、VAL520
• Inhibitors Of Beta-Secretase
  申请人：Dillard Lawrence W.

  公开号：US20110218192A1

  公开（公告）日：2011-09-08

  The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described.

  本发明涉及以下结构式所表示的化合物或其药学上可接受的盐。还描述了包含由结构式（I）所表示的化合物的药物组合物和使用这些化合物抑制需要此类治疗的受体中的BACE活性的方法。
• INHIBITORS OF BETA-SECRETASE
  申请人：Dillard Lawrence W.

  公开号：US20130317014A1

  公开（公告）日：2013-11-28

  The present invention is directed to a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound represented by Structural Formula (I) and method of use of these compound for inhibiting BACE activity in a subject in need of such treatment are also described.

  本发明涉及以下结构式所代表的化合物：或其药学上可接受的盐。还描述了包括结构式（I）所代表的化合物的药物组合物以及使用这些化合物抑制需要此类治疗的受体中的BACE活性的方法。
• US8450308B2
  申请人：——

  公开号：US8450308B2

  公开（公告）日：2013-05-28
• US8921359B2
  申请人：——

  公开号：US8921359B2

  公开（公告）日：2014-12-30